As the global economy evolves, pharmaceutical companies are becoming increasingly global in their mindsets and actions.  As a result, L&D teams must work more effectively across markets to achieve business objectives.

For L&D, “going global” can offer a range of benefits. However, there are challenges that L&D teams must address as they transition to a global footprint.

This paper collects input that was shared at a workshop on this topic at the LTEN Annual Meeting in Grapevine, TX on June 4, 2019. The workshop was led by George Schmidt of Salience Learning and Kerstin Hartig of Bristol-Myers Squibb. This paper outlines the following:

1. Why Should L&D Work Globally?
2. Benefits of a Global Footprint
3. Key Challenges Associated with Going Global.
4. Addressing the Challenges: Potential Solutions and Lessons Learned from BMS’ Transition to a Global L&D Organization